CME Presentations
VHL and RCC
Presentations
Promising Data and Novel Therapies for Hereditary RCC: Highlight on VHL-Associated RCC
Speakers: Brian Rini, MD, Chief of Clinical Trials, Ingram Professor of MedicineEric Jonasch, MD, Professor of Genitourinary Medical Oncology Graduate School of Biomedical Sciences Duration: 60 minutes
Presented on: October 29, 2021
What’s New in the Treatment Approach for Untreated and Relapsed/Refractory Advanced RCC
Speakers: Brian Rini, MD, Chief of Clinical Trials, Ingram Professor of MedicineEric Jonasch, MD, Professor of Genitourinary Medical Oncology Graduate School of Biomedical Sciences Duration: 60 minutes
Presented on: October 29, 2021
Speakers
Brian Rini, MD
Brian Rini, MD
Chief of Clinical Trials, Ingram Professor of Medicine
Brian I. Rini, MD, FASCO, is professor of medicine and chief of clinical trials for the Vanderbilt Ingram Cancer Center (VICC) at Vanderbilt University in Nashville, Tennessee. His primary research has been in renal cell carcinoma, with special focus on antiangiogenic therapy and immunotherapy. Dr Rini’s research has been published in peer-reviewed journals, including the New England Journal of Medicine, Journal of the National Cancer Institute, Journal of Clinical Oncology, and Lancet. Certified in Medical Oncology by the American Board of Internal Medicine, he is active in numerous professional organizations, such as ASCO and the Society for Immunotherapy of Cancer (SITC). Dr Rini earned his medical degree at the Ohio State University College of Medicine in Columbus.Eric Jonasch, MD
Eric Jonasch, MD
Professor of Genitourinary Medical Oncology Graduate School of Biomedical Sciences
CME Information
Renal Cell Carcinoma Summit Novel Agents and Clinical Controversies in Hereditary and Acquired RCC
ACKNOWLEDGEMENT
Supported by educational grants from AVEO Pharmaceuticals, Inc., Exelixis, and Novartis and Merck.TUITION
Complimentary
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.LIVE CREDIT DESIGNATION STATEMENT
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ENDURING CREDIT DESIGNATION STATEMENT
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.DATE OF RELEASE/EXPIRATION
Live Activity
Friday, October 29, 2021, at 10:30am – 11:30am EST
Friday, October 29, 2021, at 11:30am – 12:30pm ESTEnduring Material
October 29, 2021 – October 29, 2022.LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:- Review recent advances in research and clinical trials in hereditary RCC
- Evaluate the clinical safety and efficacy data emerging for patients with VHL-associated RCC
- Integrate new and emerging evidence into adjuvant and frontline treatment regimens for advanced RCC
- Discuss advantages and disadvantages of current and emerging second- or third-line treatments for advanced RCC
TARGET AUDIENCE
The intended audience for this activity program are medical and genitourinary oncologists, urologists, nephrologists, nurse practitioners, physician assistants, and other members of the RCC treatment team.ESTIMATED TIME TO COMPLETE
This activity should take approximately 1 hour to complete.METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com or www.ClinicalSeriesLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:Name of Faculty or Presenter Reported Financial Relationship Brian I. Rini, MD
Chief of Clinical Trials, Ingram Professor of Medicine
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical CenterConsulting Fees (e.g., advisory boards): Aveo, BMS, Exelixis, Merck, and Pfizer
Contracted Research: Aveo, BMS, Exelixis, Merck, and PfizerEric Jonasch, MD
Professor of Genitourinary Medical Oncology Graduate School of Biomedical Sciences
Division of Cancer Medicine
Houston, TXConsulting Fees (e.g., advisory boards): Aveo, Aravive, Calithera, Eisai, Exelixis, Ipsen, Merck, NiKang, Novartis, and Pfizer
Contracted Research: Merck, Nikang, Novartis
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLCNone
The PIM planners and managers have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive.com.com or ClinicalSeriesLive.com at 1-877-394-1306 or at Support@OMedLive.com.